What's the role of obesity in adjusting cosentyx doses?

Does obesity change how Cosentyx (secukinumab) is dosed?

Cosentyx dosing is not adjusted based on body weight or obesity. Standard dosing is used for approved indications, with the same regimen regardless of a patient’s weight category. [1]

Why isn’t Cosentyx dosing weight-based?

Secukinumab is a monoclonal antibody designed to target interleukin-17A, and its labeling dosing strategy does not require weight-based adjustments. Clinical use follows the fixed induction and maintenance schedule for each condition rather than using body weight to calculate dose. [1]

What dosing regimen should patients follow if they have obesity?

Patients with obesity follow the same Cosentyx schedule as other patients for their diagnosis, including the usual induction period and then the maintenance dosing option that matches the specific condition being treated. Obesity does not alter the schedule. [1]

Are there any exceptions—like severe obesity, pregnancy, or kidney/liver problems?

The available prescribing information provided here does not specify any dose adjustment for obesity. It also does not indicate a need to change Cosentyx dosing specifically because of obesity. Any changes would be based on clinical factors covered by the label (not on weight/obesity itself). [1]

What patients often ask next: will obesity affect how well Cosentyx works?

The question of effectiveness in obesity is separate from dose adjustment. Even when dose does not change, outcomes can vary by factors such as disease severity and individual response. The key point for dosing is that obesity itself does not change the prescribed Cosentyx dose. [1]

Sources

1. https://www.cosentyx.com/how-to-take-cosentyx/dosing-and-administration